Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

161. Alogliptin/metformin (Vipdomet®)

Alogliptin/metformin (Vipdomet®) Alogliptin/metformin (Vipdomet®) Alogliptin/metformin (Vipdomet®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Alogliptin/metformin (Vipdomet®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales (...) Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 3314. 2014 Authors' conclusions Alogliptin/metformin (Vipdomet®) is recommended as an option for restricted use for dual oral therapy within NHS Wales. Alogliptin/metformin (Vipdomet®) should be restricted for use in the following circumstances within its licensed indication for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus: • As an adjunct to diet and exercise to improve glycaemic

2015 Health Technology Assessment (HTA) Database.

162. Synjardy - empagliflozin / metformin

Synjardy - empagliflozin / metformin 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 26 March 2015 EMA/238334/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Synjardy International non-proprietary name: empagliflozin / metformin Procedure No. EMEA/H/C/003770/0000 Note Assessment report as adopted (...) lipoprotein LOCF Last observation carried forward Assessment report EMA/238334/2015 Page 4/99 MDRD Modification of Diet in Renal Disease MedDRA Medical dictionary for drug regulatory activities Met Metformin MMRM Mixed model repeated measures NDA New Drug Application NCF Non-completers considered failure OC Observed cases Pio Pioglitazone PIP Paediatric Investigational Plan PT Preferred term qd Once-daily SAF Safety trial grouping SBP Systolic blood pressure SD Standard deviation SE Standard error SGLT

2015 European Medicines Agency - EPARs

163. Ebymect - dapagliflozin / metformin

Ebymect - dapagliflozin / metformin 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 24 September 2015 EMA/679419/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Ebymect International non-proprietary name: dapagliflozin / metformin Procedure No. EMEA/H/C/004162/0000 Note Assessment report as adopted (...) and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control • in patients inadequately controlled on their maximally tolerated dose of metformin alone • in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products (see sections 4.4, 4.5 and 5.1 for available data on different combinations) • in patients already being treated with the combination

2015 European Medicines Agency - EPARs

164. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. (Full text)

Metformin in patients with type 2 diabetes and kidney disease: a systematic review. Metformin is widely viewed as the best initial pharmacological option to lower glucose concentrations in patients with type 2 diabetes mellitus. However, the drug is contraindicated in many individuals with impaired kidney function because of concerns of lactic acidosis.To assess the risk of lactic acidosis associated with metformin use in individuals with impaired kidney function.In July 2014, we searched (...) the MEDLINE and Cochrane databases for English-language articles pertaining to metformin, kidney disease, and lactic acidosis in humans between 1950 and June 2014. We excluded reviews, letters, editorials, case reports, small case series, and manuscripts that did not directly pertain to the topic area or that met other exclusion criteria. Of an original 818 articles, 65 were included in this review, including pharmacokinetic/metabolic studies, large case series, retrospective studies, meta-analyses

2014 JAMA PubMed

165. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses

Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses Zhang Q, Dou J, Lu J CRD summary This review (...) concluded that sodium-glucose linked transporter 2 (SGLT2) inhibitors plus metformin could be effective for patients with type 2 diabetes, based on glycaemic control, body weight and blood pressure. The authors' conclusions reflect the short-term evidence (up to 24 weeks), but the longer term data (one year and two years) were less reliable. Authors' objectives To assess sodium-glucose linked transporter 2 (SGLT2) inhibitors, with metformin, for the management of patients with type 2 diabetes under

2014 DARE.

166. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. (Full text)

Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied. Metformin reduces hyperinsulinaemia and suppresses the excessive ovarian production of androgens. As a consequence, it is suggested that metformin could improve assisted reproductive techniques (ART (...) ) outcomes, such as ovarian hyperstimulation syndrome (OHSS), pregnancy and live birth rates.To determine the effectiveness and safety of metformin as a co-treatment during IVF or intracytoplasmic sperm injection (ICSI) in achieving pregnancy or live birth in women with PCOS.We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, EMBASE, LILACS, the metaRegister of Controlled Trials

2014 Cochrane PubMed

167. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects

Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects Prescrire IN ENGLISH - Spotlight ''Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects '', 1 November 2014 {1} {1} {1} | | > > > Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects Spotlight Every month (...) , the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects FEATURED REVIEW The efficacy of metformin in type 2 diabetes is still thinly documented in 2014. However, an abundance of data is now available on its adverse effects. The evidence is relatively weak

2014 Prescrire

168. Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin (Full text)

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin This study compared the efficacy and safety of dual add-on of saxagliptin plus dapagliflozin versus saxagliptin and dapagliflozin added on alone in patients with type 2 diabetes poorly controlled with metformin.This was a double-blind trial in adults with HbA1c ≥8.0 (...) % and ≤12.0% (64-108 mmol/mol), randomized to saxagliptin (SAXA) (5 mg/day) plus dapagliflozin (DAPA) (10 mg/day; n = 179), or SAXA (5 mg/day) and placebo (n = 176), or DAPA (10 mg/day) and placebo (n = 179) on background metformin extended release (MET) ≥1,500 mg/day. Primary objective compared changes from baseline in HbA1c with SAXA+DAPA+MET versus SAXA+MET and DAPA+MET.Patients had a mean baseline HbA1c of 8.9% (74 mmol/mol), diabetes duration of 7.6 years, and a BMI of 32 kg/m(2). At week 24

2014 EvidenceUpdates PubMed

169. Linagliptin/metformin (Jentadueto) - for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy)

Linagliptin/metformin (Jentadueto) - for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) Final Appraisal Recommendation Advice No: 2114 – July 2014 Linagliptin/metformin (Jentadueto ® ? ) 2.5 mg/850 mg and 2.5 mg/1,000 mg film-coated tablets Submission by Boehringer Ingelheim Ltd/Eli Lilly & Co Ltd Additional note: • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching (...) Services and will be considered for review in three years. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2114: Linagliptin/metformin (Jentadueto ® ? ) 2.5 mg/850 mg and 2.5 mg/1,000 mg film-coated tablets. July 2014. Recommendation of AWMSG Linagliptin/metformin (Jentadueto ® ? ) is recommended as an option for use within NHS Wales

2014 All Wales Medicines Strategy Group

170. Dapagliflozin/metformin - Benefit assessment according to §35a Social Code Book V

Dapagliflozin/metformin - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dapagliflozin/Metformin – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 May 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A14-07 Dapagliflozin/metformin (...) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A14-07 Version 1.0 Dapagliflozin/metformin – Benefit assessment acc. to §35a SGB V 12 May 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dapagliflozin/metformin – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 5 February 2014

2014 Institute for Quality and Efficiency in Healthcare (IQWiG)

171. Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials

Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic (...) review of randomized controlled trials Gao W, Dong J, Liu J, Li Y, Liu F, Yang L, Zhou X, Liao L CRD summary The authors concluded that compared with equal-dosage metformin monotherapy, initial combination of metformin and dipeptidyl peptidase-IV inhibitors was more effective in type 2 diabetes glycaemic control without additional risk of adverse events. Although the authors’ conclusions reflect the results, the varied patients and treatments plus the lack of reporting of trial quality mean

2014 DARE.

172. [Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)]

[Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Dapagliflozin/Metformin – Nutzenbewertung gemäß § 35a SGB V [Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Dapagliflozin/Metformin – Nutzenbewertung gemäß § 35a SGB V [Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Dapagliflozin/Metformin – Nutzenbewertung gemäß § 35a SGB V. [Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 220. 2014 Final publication URL Indexing Status Subject indexing assigned

2014 Health Technology Assessment (HTA) Database.

173. Saxagliptin + metformin - Diabetes Mellitus, Type 2

Saxagliptin + metformin - Diabetes Mellitus, Type 2 Common Drug Review CDEC Meeting — May 21, 2014 Notice of Final Recommendation — June 20, 2014 Page 1 of 4 © 2014 CADTH CDEC FINAL RECOMMENDATION SAXAGLIPTIN / METFORMIN (Komboglyze — AstraZeneca) Indication: Type 2 Diabetes Mellitus Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that saxagliptin/metformin (Komboglyze) be listed for patients if the following clinical criterion and condition are met: Clinical Criterion (...) : ? Patients for whom insulin is not an option and who are already stabilized on therapy with metformin, a sulfonylurea and saxagliptin, to replace the individual components of saxagliptin and metformin in these patients. Condition: ? Drug plan costs for the saxagliptin/metformin fixed-dose combination (FDC) should not exceed the combined cost of saxagliptin and metformin administered separately. Reason for the Recommendation: At the submitted price, the saxagliptin/metformin FDC ($2.54 per day) is less

2014 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

174. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone (Full text)

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone.In this randomized, double-blind, phase 3 study, patients (N = 342) received canagliflozin 100 or 300 mg during a 26-week, placebo-controlled, core period and a 26-week (...) rates were low. Incidences of genital mycotic infections and AEs related to osmotic diuresis and volume depletion were higher with canagliflozin than placebo/sitagliptin.Canagliflozin improved glycaemic control, reduced body weight and systolic BP, and was generally well tolerated in patients with T2DM on metformin and pioglitazone over 52 weeks.© 2014 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

2014 EvidenceUpdates PubMed

175. Vildagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Vildagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment) Vildagliptin/metformin – nutzenbewertung gemäß § 35a SGB V [Vildagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Vildagliptin/metformin – nutzenbewertung gemäß § 35a SGB V [Vildagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Vildagliptin/metformin – nutzenbewertung gemäß § 35a SGB V. [Vildagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 179. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH

2014 Health Technology Assessment (HTA) Database.

176. Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment) Sitagliptin/metformin – nutzenbewertung gemäß § 35a SGB V [Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Sitagliptin/metformin – nutzenbewertung gemäß § 35a SGB V [Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Sitagliptin/metformin – nutzenbewertung gemäß § 35a SGB V. [Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 176. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes

2014 Health Technology Assessment (HTA) Database.

177. Saxagliptin/Metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Saxagliptin/Metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment) Saxagliptin/Metformin (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Saxagliptin/Metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Saxagliptin/Metformin (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Saxagliptin/Metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Saxagliptin/Metformin (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V. [Saxagliptin/Metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 167. 2013 Final publication URL

2014 Health Technology Assessment (HTA) Database.

178. Addendum to commission A13-17 (vildagliptin/metformin)

Addendum to commission A13-17 (vildagliptin/metformin) Addendum zum auftrag A13-17 (vildagliptin/metformin) [Addendum to commission A13-17 (vildagliptin/metformin)] Addendum zum auftrag A13-17 (vildagliptin/metformin) [Addendum to commission A13-17 (vildagliptin/metformin)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG (...) . Addendum zum auftrag A13-17 (vildagliptin/metformin). [Addendum to commission A13-17 (vildagliptin/metformin)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 189. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Metformin; Nitriles; Pyrrolidines Language Published German Country of organisation Germany English summary There is no English

2014 Health Technology Assessment (HTA) Database.

179. Addendum to commission A13-03 (sitagliptin/metformin)

Addendum to commission A13-03 (sitagliptin/metformin) Addendum zum auftrag A13-03 (sitagliptin/metformin) [Addendum to commission A13-03 (sitagliptin/metformin)] Addendum zum auftrag A13-03 (sitagliptin/metformin) [Addendum to commission A13-03 (sitagliptin/metformin)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Addendum (...) zum auftrag A13-03 (sitagliptin/metformin). [Addendum to commission A13-03 (sitagliptin/metformin)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 187. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 2; Hypoglycemic Agents; Metformins; Pyrazines; Triazoles Language Published German Country of organisation Germany English summary There is no English language summary available. Address

2014 Health Technology Assessment (HTA) Database.

180. Metformin

Metformin USE OF METFORMIN IN PREGNANCY 0344 892 0909 USE OF METFORMIN IN PREGNANCY (Date of issue: September 2017 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Metformin is an antihyperglycaemic biguanide used in the management (...) of type 2 diabetes. It acts by lowering basal and postprandial plasma glucose without stimulating insulin secretion, thereby reducing the risk of hypoglycaemia associated with insulin therapy. Metformin is also used off-label for the treatment of infertility secondary to polycystic ovarian syndrome (PCOS). The available data do not show an increased risk of congenital malformation, spontaneous abortion, preterm delivery, small or large for gestational age infants, perinatal mortality or neonatal

2014 UK Teratology Information Service